Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Karin Laglas | F | 64 |
University of Utrecht
| - |
| Roel Q. J. Schaapveld | M | - |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 16 years |
| Hans Clevers | M | 67 |
Hubrecht Institute
 Hubrecht Institute BiotechnologyHealth Technology The Hubrecht Institute is a research institute that focuses on fundamental, multidisciplinary research on healthy and diseased cells, tissues, and organisms. The location of the private company is in Utrecht, Netherlands. The institute encompasses 23 research groups dedicated to this mission.
University of Utrecht
| 35 years |
| Eugene Berezikov | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.
Hubrecht Institute
Hubrecht Institute BiotechnologyHealth Technology The Hubrecht Institute is a research institute that focuses on fundamental, multidisciplinary research on healthy and diseased cells, tissues, and organisms. The location of the private company is in Utrecht, Netherlands. The institute encompasses 23 research groups dedicated to this mission. | 18 years |
| Brian S. Bronk | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
| Henk Kummeling | M | - |
University of Utrecht
| - |
| Jeroen Hertog | M | - |
Hubrecht Institute
Hubrecht Institute BiotechnologyHealth Technology The Hubrecht Institute is a research institute that focuses on fundamental, multidisciplinary research on healthy and diseased cells, tissues, and organisms. The location of the private company is in Utrecht, Netherlands. The institute encompasses 23 research groups dedicated to this mission. | - |
| Alexander van Oudenaarden | M | - |
Hubrecht Institute
Hubrecht Institute BiotechnologyHealth Technology The Hubrecht Institute is a research institute that focuses on fundamental, multidisciplinary research on healthy and diseased cells, tissues, and organisms. The location of the private company is in Utrecht, Netherlands. The institute encompasses 23 research groups dedicated to this mission. | - |
| Wilko de Vette | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
| Samuel Gerssen | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
| Lucas de Breed | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
| Albert Osterhaus | M | - |
University of Utrecht
| - |
| Andrea van Elsas | M | 58 |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 3 years |
| Lambert Meertens | M | - |
University of Utrecht
| - |
| Jan van de Winkel | M | 63 |
University of Utrecht
| 28 years |
| Martin J. M. Tielen | M | 81 |
University of Utrecht
| - |
| Steven R. Schuit | M | 81 |
University of Utrecht
| - |
| J. P. Bahlmann | M | 74 |
University of Utrecht
| - |
| Johannes G. C. P. Schikan | M | 66 |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 9 years |
| Jeroen F. J. M. de Haas | M | 65 |
University of Utrecht
| - |
| Jan M. van der Eijk | M | 64 |
University of Utrecht
| - |
| Mark de Boer | M | 64 |
University of Utrecht
| - |
| Hans J. W. de Haard | M | 64 |
University of Utrecht
| - |
| René Bernards | M | 72 |
University of Utrecht
| - |
| Graham Dixon | M | 63 |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
| Margot van der Starre | F | - |
University of Utrecht
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Erik Lars Alfred van Emden | M | 76 |
Radboud University Nijmegen
| 3 years |
| Freek T.A.M. Welling | M | - |
Radboud University Nijmegen
| 6 years |
| Marcel Van De Pol | M | - |
Radboud University Nijmegen
| 3 years |
| Yaser Bishr | M | - |
Wageningen University
| 3 years |
| Erik Vossenaar | M | 51 |
Radboud University Nijmegen
| 1 years |
| Dirk-Jan H. Arts | M | - |
Radboud University Nijmegen
| 5 years |
| Przemyslaw Glebocki | M | 44 |
Radboud University Nijmegen
| 4 years |
| Jeroen Dijsselbloem | M | 58 |
Wageningen University
| 6 years |
| Rien Nagel | M | - |
Radboud University Nijmegen
| 4 years |
| Hans van Eenennaam | M | - |
Radboud University Nijmegen
| 3 years |
| Mark Vaeck | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
| Grégoire Pierre Prevost | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
| Jozef J. W. M. Mertens | M | - |
Wageningen University
| 3 years |
| André van Puijenbroek | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
| Louise Ottilie Fresco | M | 72 |
Wageningen University
| 7 years |
| Stefan Ten Brink | M | - |
Radboud University Nijmegen
| 2 years |
| Marnix A. Snijder | M | 78 |
Radboud University Nijmegen
| 8 years |
| Marc Weeber | M | - |
Radboud University Nijmegen
| 1 years |
| Gaston van de Poel | M | 59 |
Radboud University Nijmegen
| 2 years |
| Geert Corstens | M | - |
Radboud University Nijmegen
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Netherlands | 46 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Edwin Cuppen
- Personal Network
